Noninferiority field trial for evaluation of efficacy of ciprofloxacin associated with internal teat sealant as dry-off protocol

Trop Anim Health Prod. 2019 Nov;51(8):2547-2557. doi: 10.1007/s11250-019-01955-6. Epub 2019 Jun 20.

Abstract

The aim of this study was to compare the efficacy of two dry-off protocols: (a) dry cow therapy using ciprofloxacin hydrochloride 400 mg followed by the administration of an internal teat sealant composed of 4 g of bismuth subnitrate, and (b) a positive control using dry cow therapy with 250 mg cephalonium followed by the administration of 2.6 g bismuth subnitrate internal teat sealant. A total of 578 Holstein cows selected from 7 commercial herds were randomly allocated into two groups at drying off: (a) ciprofloxacin hydrochloride 400 mg (CH) associated with ITS, n = 1112 mammary quarters/296 cows, or (b) positive control (PC) = cephalonium (250 mg) associated with ITS, n = 1058 mammary quarters/282 cows). A total of 1787 out of 2170 mammary quarters (82%) had negative culture at drying off. The microorganisms most frequently isolated at drying off were CNS (5.62%), Strep. uberis (1.9%), Corynebacterium spp. (1.8%), and Staphylococcus aureus (1.01%). A total of 465 mammary quarters experienced new intramammary infections (NIMIs), and the main microorganisms causing NIMI were CNS (21.94%), Strep. uberis (17.2%), and Pseudomonas spp. (9.7%). The CH protocol was not inferior to PC, as the cure risk of mammary quarters CH-treated was at the noninferiority limit. However, the mammary quarters treated by CH protocol had 24% and 31% lower risk of overall NIMI and NIMI caused by major pathogens, respectively, than mammary quarters dried with the PC protocol. In addition, the mammary quarters treated with CH protocol had a lower risk of CM through the first 60 DIM than those treated with PC protocol. Both DCT protocols showed similar odds of microbiological cure, but the CH protocol had greater prevention against NIMI during dry-off period.

Keywords: Cephalonium; Dry-cow therapy; Mastitis; New IMI; Noninferiority.

Publication types

  • Randomized Controlled Trial, Veterinary

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Bismuth / therapeutic use
  • Brazil / epidemiology
  • Cattle
  • Cephalosporins / therapeutic use*
  • Ciprofloxacin / therapeutic use*
  • Corynebacterium / isolation & purification
  • Corynebacterium Infections / drug therapy
  • Corynebacterium Infections / epidemiology
  • Corynebacterium Infections / microbiology
  • Corynebacterium Infections / veterinary
  • Female
  • Incidence
  • Lactation
  • Mammary Glands, Animal / drug effects
  • Mammary Glands, Animal / microbiology*
  • Mastitis, Bovine / drug therapy*
  • Mastitis, Bovine / microbiology
  • Prevalence
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / epidemiology
  • Staphylococcal Infections / microbiology
  • Staphylococcal Infections / veterinary
  • Staphylococcus / isolation & purification
  • Streptococcal Infections / drug therapy
  • Streptococcal Infections / epidemiology
  • Streptococcal Infections / microbiology
  • Streptococcal Infections / veterinary
  • Streptococcus / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Ciprofloxacin
  • bismuth subnitrate
  • cephalonium
  • Bismuth